Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Maxacalcitol · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Paricalcitol 2 µg ± 1 µg | EXPERIMENTAL | Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg |
| Paricalcitol 2 µg ± 2 µg | EXPERIMENTAL | Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg |
| Paricalcitol 4 µg ± 1 µg | EXPERIMENTAL | Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg |
| Paricalcitol 4 µg ± 2 µg | EXPERIMENTAL | Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg |
| Maxacalcitol 5 or 10 µg ± 2.5 µg | OTHER | Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg |
| Name | Type | Description |
|---|---|---|
| Maxacalcitol | DRUG | Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks. |
| Paricalcitol | DRUG | Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks. |
Inclusion Criteria: * Diagnosed with chronic kidney disease receiving hemodialysis 3 times a week for at least 3 months prior to obtaining the informed consent and scheduled to be receiving the same hemodialysis during the study period. * Using dialysate with constant concentration of calcium for 4...
Maxacalcitol is a small molecule being developed for Chronic Kidney Disease on Hemodialysis. It is being studied for its effects on secondary hyperparathyroidism in patients receiving hemodialysis. The drug is currently in Phase 2 clinical development.
Maxacalcitol is being developed by Abbott Laboratories, which trades under the ticker ABT. The company is conducting clinical research on this drug for the treatment of chronic kidney disease patients on hemodialysis.
Maxacalcitol is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its potential use in chronic kidney disease patients on hemodialysis.
Maxacalcitol has one completed clinical trial, NCT00667576, which was a Phase 2 dose-response study of paricalcitol injection in chronic kidney disease patients receiving hemodialysis. The trial enrolled 153 participants in Japan and was controlled but not double-blind.
Maxacalcitol is not the same as paricalcitol. The clinical trial NCT00667576 studied paricalcitol injection, not Maxacalcitol. Maxacalcitol is a separate drug being developed by Abbott Laboratories for chronic kidney disease on hemodialysis.